Skip to main content
. 2018 Apr 19;9(10):1791–1796. doi: 10.7150/jca.25132

Figure 1.

Figure 1

Figure 1

Progression-free survival (PFS) to bevacizumab-containing chemotherapy in overall patients (A), according to the status of microsatellite instability (B), the location of the primary tumor (C), and the treatment-line of bevacizumab-containing chemotherapy (D)